Volume 14 - Issue 4 - April, 2002
Feature
08/01/2008
Frank V. Aguirre, MD and John B. Gill, MD
Frank V. Aguirre, MD and John B. Gill...
Despite technologic and therapeutic advances, both ischemic and hemorrhagic complications remain the most common risks associated with percutaneous coronary interventions (PCI). Contemporary PCI trials typically focus on reducing ischemic...
Despite technologic and therapeutic advances, both ischemic and hemorrhagic complications remain the most common risks associated with percutaneous coronary interventions (PCI). Contemporary PCI trials typically focus on reducing ischemic...
Despite technologic and...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Recent advances in catheter technology and antithrombotic therapy have led to a continuous improvement in outcomes of percutaneous coronary intervention (PCI). These improved outcomes have been associated with broadening of the indications...
Recent advances in catheter technology and antithrombotic therapy have led to a continuous improvement in outcomes of percutaneous coronary intervention (PCI). These improved outcomes have been associated with broadening of the indications...
Recent advances in catheter...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Continued from previous page
Bleeding complications in practice. Demographics and definitions. As mentioned previously, data from multi- and single-center registries of PCI report much higher bleeding complication rates than those seen in...
Continued from previous page
Bleeding complications in practice. Demographics and definitions. As mentioned previously, data from multi- and single-center registries of PCI report much higher bleeding complication rates than those seen in...
Continued from previous...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Adverse outcomes of PCI include myocardial ischemia and necrosis, the need for endovascular or surgical reintervention, and occasionally death.1–3 Routine pharmacologic therapy includes antiplatelet and antithrombotic agents. Heparin has been...
Adverse outcomes of PCI include myocardial ischemia and necrosis, the need for endovascular or surgical reintervention, and occasionally death.1–3 Routine pharmacologic therapy includes antiplatelet and antithrombotic agents. Heparin has been...
Adverse outcomes of PCI include...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Continued from previous page
Overcoming heparin limitations in PCI with direct thrombin inhibitors
Direct thrombin inhibitors, i.e., univalent agents such as argatroban, and bivalent agents such as lepirudin (Refludan®), desirudin (Revasc®)...
Continued from previous page
Overcoming heparin limitations in PCI with direct thrombin inhibitors
Direct thrombin inhibitors, i.e., univalent agents such as argatroban, and bivalent agents such as lepirudin (Refludan®), desirudin (Revasc®)...
Continued from previous...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
ABSTRACT: The clinical implications of even mild impairment of renal function in percutaneous coronary interventions (PCI) have, to date, been poorly appreciated. The progressive loss of renal function is marked by the onset of a...
ABSTRACT: The clinical implications of even mild impairment of renal function in percutaneous coronary interventions (PCI) have, to date, been poorly appreciated. The progressive loss of renal function is marked by the onset of a...
ABSTRACT: The clinical...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Since Andreas Gruentzig first introduced coronary angioplasty in 1977, clinicians have been driven to lower the risks associated with the procedure and improve patient outcomes. Improvements in catheter technology as well as the clinician’s...
Since Andreas Gruentzig first introduced coronary angioplasty in 1977, clinicians have been driven to lower the risks associated with the procedure and improve patient outcomes. Improvements in catheter technology as well as the clinician’s...
Since Andreas Gruentzig first...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Heparin has served an important role in percutaneous coronary interventions (PCI) as the standard antithrombin agent since the procedure was first introduced. Modifications in heparin therapy and technological advancements have improved...
Heparin has served an important role in percutaneous coronary interventions (PCI) as the standard antithrombin agent since the procedure was first introduced. Modifications in heparin therapy and technological advancements have improved...
Heparin has served an important...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Jeffrey I. Weitz, MD and Shannon M. Bates, MD, CM
Jeffrey I. Weitz, MD and Shannon M. B...
Acute coronary syndromes (ACS) are usually caused by thrombosis superimposed on disrupted atherosclerotic plaque.1 Intracoronary thrombi, which form under high shear conditions, are composed of platelet aggregates held together by fibrin...
Acute coronary syndromes (ACS) are usually caused by thrombosis superimposed on disrupted atherosclerotic plaque.1 Intracoronary thrombi, which form under high shear conditions, are composed of platelet aggregates held together by fibrin...
Acute coronary syndromes (ACS)...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Jonathan D. Marmur, MD, FACC
Jonathan D. Marmur, MD, FACC
Heparin
Heparin has been used to prevent intravascular thrombosis and clotting on the surface of equipment used during percutaneous coronary interventions (PCI) since Andreas Gruentzig performed the first angioplasty.1 In fact, the...
Heparin
Heparin has been used to prevent intravascular thrombosis and clotting on the surface of equipment used during percutaneous coronary interventions (PCI) since Andreas Gruentzig performed the first angioplasty.1 In fact, the...
Heparin
Heparin has been used...
08/01/2008
Journal of Invasive Cardiology
